Fate Therapeutics Receives $15M CIRM Grant for FT819 Phase 2 Trial

What Happened
Fate Therapeutics announced that the California Institute for Regenerative Medicine (CIRM) awarded the company a $15.0 million grant on September 25, 2026 to support its Phase 2 RECLAIM-LN clinical trial of FT819. The company issued a press release the same day and filed a Form 8‑K on September 28, 2026 reporting the award under Item 8.01.

Key Details

• Grantor: California Institute for Regenerative Medicine (CIRM).
• Amount: $15.0 million awarded on September 25, 2026.
• Purpose: To support Fate’s Phase 2 RECLAIM-LN clinical trial of FT819.
• Public filing: Press release issued September 25, 2026 and included as Exhibit 99.1 to the Form 8‑K filed September 28, 2026.

Why It Matters
The $15M award is non-dilutive funding designated for clinical development of FT819, which can help cover trial costs and reduce near-term cash required from investors or financing. Support from CIRM also signals continued institutional backing for the program. Investors should watch for subsequent clinical updates, trial milestones, and disclosures on how the grant will be allocated within the RECLAIM-LN program.